Exact Mass: 543.1725210000001
Exact Mass Matches: 543.1725210000001
Found 54 metabolites which its exact mass value is equals to given mass value 543.1725210000001
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Doxorubicin
Doxorubicin is only found in individuals that have used or taken this drug. It is antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of daunorubicin. [PubChem]Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors KEIO_ID D064
Epirubicin
Epirubicin is only found in individuals that have used or taken this drug. It is an anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. [PubChem]Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors Same as: D07901
Puromycin hydrochloride
Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis[1].
Triferric doxorubicin
Doxorubicin
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors
Epirubicin
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent An anthracycline that is the 4-epi-isomer of doxorubicin. D004791 - Enzyme Inhibitors Same as: D07901
Cys Met Gln Tyr
C22H33N5O7S2 (543.1821308000001)
Cys Met Tyr Gln
C22H33N5O7S2 (543.1821308000001)
Cys Gln Met Tyr
C22H33N5O7S2 (543.1821308000001)
Cys Gln Tyr Met
C22H33N5O7S2 (543.1821308000001)
Cys Tyr Met Gln
C22H33N5O7S2 (543.1821308000001)
Cys Tyr Gln Met
C22H33N5O7S2 (543.1821308000001)
Met Cys Gln Tyr
C22H33N5O7S2 (543.1821308000001)
Met Cys Tyr Gln
C22H33N5O7S2 (543.1821308000001)
Met Gln Cys Tyr
C22H33N5O7S2 (543.1821308000001)
Met Gln Tyr Cys
C22H33N5O7S2 (543.1821308000001)
Met Tyr Cys Gln
C22H33N5O7S2 (543.1821308000001)
Met Tyr Gln Cys
C22H33N5O7S2 (543.1821308000001)
Gln Cys Met Tyr
C22H33N5O7S2 (543.1821308000001)
Gln Cys Tyr Met
C22H33N5O7S2 (543.1821308000001)
Gln Met Cys Tyr
C22H33N5O7S2 (543.1821308000001)
Gln Met Tyr Cys
C22H33N5O7S2 (543.1821308000001)
Gln Tyr Cys Met
C22H33N5O7S2 (543.1821308000001)
Gln Tyr Met Cys
C22H33N5O7S2 (543.1821308000001)
Tyr Cys Met Gln
C22H33N5O7S2 (543.1821308000001)
Tyr Cys Gln Met
C22H33N5O7S2 (543.1821308000001)
Tyr Met Cys Gln
C22H33N5O7S2 (543.1821308000001)
Tyr Met Gln Cys
C22H33N5O7S2 (543.1821308000001)
Tyr Gln Cys Met
C22H33N5O7S2 (543.1821308000001)
Tyr Gln Met Cys
C22H33N5O7S2 (543.1821308000001)
Puromycin dihydrochloride
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis[1].
1,2-dihydro-6-hydroxy-4-methyl-2-oxo-5-[[4-(phenylazo)phenyl]azo]-1,3-bipyridinium malate
2-[2-[2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethoxy]ethoxy]ethanol
C25H35Cl2N3O4S (543.1725210000001)
(1R,2R,4S)-4-[(3-azaniumyl-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-2-ethyl-2,5,7,12-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
(7S,9S)-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[[(4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
6-(4-Benzylpiperazine-1-carbonyl)-2-[3-(trifluoromethyl)phenyl]benzo[de]isoquinoline-1,3-dione
(7R,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-Carboxy-13-deoxycarminomycin
An anthracycline antibiotic that is 13-deoxycarminomycin substituted at position 10 by a carboxy group.
7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-carboxy-13-deoxycarminomycin zwitterion
A zwitterion obtained by transfer of a proton from the carboxy to the primary amino group of 10-carboxy-13-deoxycarminomycin; major species at pH 7.3.
5'-Guanidinonaltrindole (hydrochloride)
5'-Guanidinonaltrindole (5'-GNTI) hydrochloride is a highly selective and potent κ-opioid receptor antagonist with a Ki of 0.18 nM for human κ-opioid receptor[1].
(2s,3s,4r)-4-{[(2s,3r,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-2,5,7-trihydroxy-6-imino-3-methoxy-2-methyl-3,4-dihydrotetracene-1,11-dione
4-[(4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl)oxy]-2,5,7-trihydroxy-6-imino-3-methoxy-2-methyl-3,4-dihydrotetracene-1,11-dione
(8s,9s,10r)-12-amino-10-{[(2s,3r,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-8,11-dihydroxy-9-methoxy-8-methyl-9,10-dihydrotetracene-1,5,7-trione
methyl 4-[(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy]-2,5,7,12-tetrahydroxy-2-methyl-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
(2s)-2-[(6as)-5-chloro-6a-methyl-9-(2-methylbut-2-enoyl)-3-[(1e,3s)-3-methylpent-1-en-1-yl]-6,8-dioxofuro[2,3-h]isoquinolin-2-yl]pentanedioic acid
C28H30ClNO8 (543.1659850000001)